The long-held assumption that antibodies are exquisitely specific is being re-examined since 25% of monoclonal antibodies (MAbs) show polyspecificity and bind unintended targets. Mistargeted antibodies can result in severe or life-threatening adverse events, especially when constituting the targeting domains of CAR-T cell therapies, bispecifics, or antibody-drug conjugates (ADC). Poor specificity is the largest determinant (62%) of drug failure in preclinical and early clinical studies.
This Fierce webinar brings together experts with experience in biotech, pharma, and the FDA to discuss the latest technologies and strategies to optimize IND safety data packages. Topics to be discussed include:
- Best practices to identify safe lead candidates early in development
- Traditional approaches such as tissue cross-reactivity (TCR) studies and other in vitro toxicology assays
- Emerging technologies including Integral Molecular’s Membrane Proteome Array (MPA), which tests the specificity of antibodies and CAR-T cells across an array of 6,000 native membrane proteins